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Abstract
The recent identification of copy-number variation in the human genome has opened up new avenues for the discovery of
positional candidate genes underlying complex genetic disorders, especially in the field of psychiatric disease. One major
challenge that remains is pinpointing the susceptibility genes in the multitude of disease-associated loci. This challenge may
be tackled by reconstruction of functional gene-networks from the genes residing in these loci. We applied this approach to
autism spectrum disorder (ASD), and identified the copy-number changes in the DNA of 105 ASD patients and 267 healthy
individuals with Illumina Humanhap300 Beadchips. Subsequently, we used a human reconstructed gene-network,
Prioritizer, to rank candidate genes in the segmental gains and losses in our autism cohort. This analysis highlighted several
candidate genes already known to be mutated in cognitive and neuropsychiatric disorders, including RAI1, BRD1, and
LARGE. In addition, the LARGE gene was part of a sub-network of seven genes functioning in glycobiology, present in seven
copy-number changes specifically identified in autism patients with limited co-morbidity. Three of these seven copy-
number changes were de novo in the patients. In autism patients with a complex phenotype and healthy controls no such
sub-network was identified. An independent systematic analysis of 13 published autism susceptibility loci supports the
involvement of genes related to glycobiology as we also identified the same or similar genes from those loci. Our findings
suggest that the occurrence of genomic gains and losses of genes associated with glycobiology are important contributors
to the development of ASD.
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Introduction
Autism Spectrum Disorders (ASD) consist of three disorders;
autism, Asperger syndrome, and pervasive developmental disor-
der-not otherwise specified. These disorders can be distinguished
according to symptom severity and symptom pattern, and by age
of onset of the first symptoms. ASD are characterized by three
core features: impairment in reciprocal social interactions,
communicative deficits, and repetitive and restricted patterns of
behavior and interests (Diagnostic and Statistical Manual of
Mental Disorders-fourth edition-text revision, DSM-IV-TR).
Individuals with impairments in all three areas and an age of
onset before 36 months are diagnosed with autism. The risk for
autism is mainly determined by genetic factors, as is the case for
many psychiatric disorders, with heritability estimates for autism
as high as 90% [1,2]. Despite the evidence for major genetic
contributions, the isolation of specific risk genes for autism has
proven difficult, and in only a minority of autism cases a genetic
defect can be unequivocally linked to the disease. Corresponding-
ly, replication of linkage and association findings in autism cohorts
has been problematic. The limited rate of reproducible findings
may reflect extensive heterogeneity and modest effects of disease
genes, effects of parental imprinting, and epistasis but also
heterogeneity across populations, false-positive results, systematic
bias due to technical artifacts, population stratification or
environmental modifiers [3]. Alternatively, the involvement of
rare variants may by definition be difficult to replicate across
different patient cohorts.
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Cytogenetic analysis has demonstrated a relatively high
frequency of microscopically visible chromosomal abnormalities
(3–5%) in individuals with ASD [4]. Fluorescence in situ
hybridization (FISH) and even more powerful detection methods
such as microarray-based comparative genomic hybridization
(array-CGH) have demonstrated that submicroscopic genomic
losses and gains may be causally related to autism at much higher
percentages [5,6]. These genomic gains and losses are often
referred to as copy-number variants (CNVs), and can be
transmitted by or arise de novo on both the paternal or maternal
inherited chromosomes [7]. Recently, we have reported on
clustering of autism-associated cytogenetic abnormalities in a
large sample of independent case reports [4], and several others
have reported the occurrence of multiple autism-associated CNVs
[5,6,8,9]. However, the identified loci are often large, covering
many genes, and are often ‘‘private’’ to an individual or family.
The challenge will be how to identify the causative dosage-
dependent gene(s) within these regions. While the involvement of
single gene mutations in individual autism cases cannot be
excluded, the concept of a complex genetic model with multiple
genes contributing to disease susceptibility remains highly
plausible for the majority of cases [10]. In this context it appears
to be justified to shift from a narrow focus on individual candidate
genes towards a broader view of affected gene networks and
associated biological pathways.
One approach towards the identification of such networks
involves the integration of available biological data on individual
genes, relating to their expression profile and the functional and
structural properties of the encoded proteins. Based on this
concept we have recently described a novel method for ranking
candidate genes within disease susceptibility loci based on proven
and/or putative interactions with genes present in other loci linked
to the same disorder: Prioritizer [11]. The basic premise of this
method is that the many susceptibility genes involved in a complex
disease are mostly confined to a limited number of different
biological systems and processes and therefore are likely to cluster
within a reconstructed functional human gene-network. By using
Prioritizer biological relationships between otherwise seemingly
unrelated loci can be revealed, improving the odds for selecting the
relevant candidate genes. Several other groups have since reported
slightly different bioinformatics platforms for candidate gene
prioritization, e.g. Endeavour, SUSPECTS, and ToppGene [12–
14]. However, these methods use training sets of known disease
genes and sequence similarity analysis that biases the analysis
towards a limited number of known disease genes. An important
strength of Prioritizer is that it functions without any a priori
knowledge, e.g. which gene or protein sequence, organ, functional
system, or diagnosis to look at, making it a less biased approach
compared to other methods.
Here we report the results from the application of Prioritizer to
CNVs identified in a microarray-based genome-wide CNV
analysis in a phenotypically well-defined cohort of 105 Dutch
ASD patients and 267 ethnically-matched healthy individuals, and
on 13 additional autism susceptibility loci reported in the literature
(including linkage regions and regions with recurrent genomic
gains and losses). Comparison of these datasets suggests that genes
involved in glycobiology are involved in the development of
autism.
Results
Genome-wide CNV analysis using Illumina
HumanHap300 Beadchips
We SNP-genotyped the DNA of 105 autism patients and 267
unrelated healthy controls using Illumina HumanHap300 Bead-
chips and Illumina Beadstudio analysis software (see methods for
details). The autism cohort was divided into two patient groups
according to the presence of a positive family history, growth
disorders, and dysmorphic features or congenital anomalies. The
first group consisted of patients with little or none of these
abnormalities in concurrence with autism (non-complex-autism
group, n = 53). The second group consisted of patients with more
of the aforementioned abnormalities in concurrence with autism
(complex-autism group, n = 52). The data obtained were subse-
quently analyzed for CNV content using a script previously shown
to yield highly reproducible and reliable results [15]. In total, 452
CNVs were identified in the autism subjects and 1,433 CNVs were
identified in the healthy controls. Table 1 summarizes the
characteristics of these CNVs. 112 out of the 210 CNVs in the
non-complex-autism group (53%), and 106 out of the 242 CNVs
Table 1. Characteristics of CNVs identified in 105 autism patients and 267 healthy controls.
Non-complex-autism Complex-autism Controls
(n =53) (n=52) (n =267)
CNV totals (average/individual) 210 (3.96) 242 (4.57) 1,433 (5.37)
Duplications
N 97 109 648
Mean per individual (range) 1.83 (0–5) 2.10 (0–6) 2.44 (0–10)
Mean size in kilobases (range) 327.5 (4.3–12,478.8) 170.8 (3.4–2,881.4) 143.3 (3.9–9,583.7)
Heterozygous deletions
N 109 124 771
Mean per individual (range) 2.06 (0–7) 2.38 (0–8) 2.90 (0–9)
Mean size in kilobases (range) 124.3 (2.4–554.9) 107.7 (0.8–3,043.6) 70.6 (1.0–1,348.6)
Homozygous deletions
N 4 9 14
Mean per individual (range) 0.08 (0–1) 0.17 (0–2) 0.05 (0–1)
Mean size in kilobases (range) 42.7 (6.3–93.6) 46.9 (1.1–162.2) 82.1 (4.8–190.3)
doi:10.1371/journal.pone.0005324.t001
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in the complex-autism group (48%) were not encountered in our
control cohort. The mean number of CNVs detected per
individual, irrespective of the type of aberration, did not
significantly differ between the non-complex-autism group and
complex-autism groups, or between the autism patient groups and
control cohort (Wilcoxon-Mann-Whitney (WMW) test, p.0.05).
The number of gains and losses in the non-complex-autism group
was significantly lower than observed in healthy control individuals
(WMW test, p-values for gains and losses respectively 0.031, and
0.001). In the complex-autism group, a nominally higher number
of homozygous losses was present (WMW, p= 0.026). The mean
size of the CNVs did not differ significantly between the autism
groups and healthy control group, when excluding a 12.47
megabase segmental gain spanning the centromere, identified in a
single patient in the non-complex-autism group (WMW test,
p.0.05).
Prioritizer analysis of CNVs identified in autism patients
Subsequently, we attempted to select candidate genes and
uncover shared biological processes by Prioritizer gene-network
analysis, with solely the identified CNV regions as the point of
departure. The identified CNVs were combined if they over-
lapped, resulting in 173 non-overlapping unique copy-number
variant regions (CNVR), containing 347 genes, for the non-
complex-autism group (Table S1), and 181 non-overlapping
unique CNVR, containing 221 genes, for the complex-autism
group (Table S2). Analyses were compared to 1,433 CNV regions
that had been identified in the 267 healthy controls. If CNVs in
different healthy controls overlapped, these CNVs regions were
concatenated, resulting in 869 non-overlapping unique CNVR
(containing 957 genes). We used this control dataset to control for
the fact that many CNVs are common in the population.
Additionally we used this control dataset to prevent for potential
biases due to the non-uniform genomic coverage of the
oligonucleotide array that had been used, resulting in more
conservative, yet more robust results (see Materials & Methods for
details). To eliminate biases towards genes that have many known
or predicted interactions, a so-called topology-corrected analysis
was performed (see Materials & Methods). Tables 2 and 3 show
the topology-corrected significant results of Prioritizer analysis of
the genes in CNVs found in the non-complex-autism and
complex-autism groups, respectively. The non-complex-autism
group showed an enrichment in the CNVs for interacting genes,
given the fact that the 38 genes for which Prioritizer calculated p-
values ,0.05 are substantially more then the 17 genes expected by
chance alone (0.05*347 genes). No such enrichment was observed
in CNVs of the complex-autism group, as only 5 genes had a p-
value ,0.05 whereas by chance alone 11 genes could be expected
with this score (0.05*221 genes).
Gene-network analysis of the genes highlighted by Prioritizer in
the non-complex-autism group revealed a putative gene-network
in four CNVs containing genes known to operate in glycobiology
(B3GALT6, GCNT2, LARGE, and GALNT9). Inspection of the
remaining genes in the non-complex-autism group CNVs revealed
three additional genes functioning in the same processes
Table 2. Prioritizer analysis of non-complex-autism patient
CNVs.
Gene Name Chr Gene start Gene end P-Value
RAI1 17 17,525,512 17,657,400 0.001199
S100A5 1 150,322,696 150,327,314 0.001999
SDF4 1 1,180,538 1,207,334 0.003998
C14orf147 14 33,971,905 34,001,313 0.004398
KHDRBS2 6 62,447,824 63,054,091 0.004798
ZBED4 22 48,568,390 48,602,951 0.007596
NTM 11 131,286,586 131,710,250 0.009196
ORAI3 16 30,867,916 30,873,757 0.009196
LARGE 22 31,993,401 32,640,964 0.009196
PCLO 7 82,223,443 82,436,559 0.010795
DUOXA1 15 43,196,864 43,209,367 0.011195
DPF1 19 43,394,182 43,420,994 0.012794
SETD1A 16 30,876,116 30,903,482 0.014394
ATMIN 16 79,627,142 79,636,280 0.015193
LILRB3 19 59,412,549 59,438,461 0.016393
B3GALT6 1 1,207,568 1,210,341 0.017992
GCSH 16 79,673,430 79,687,481 0.017992
LOC729920 7 16,028,931 16,234,010 0.019992
LILRA3 19 59,491,671 59,496,077 0.021591
BRD1 22 48,487,793 48,541,685 0.023990
ZC3H7B 22 40,022,067 40,080,651 0.025589
CHMP5 9 33,255,000 33,322,656 0.026789
NANOGP1 12 7,916,801 7,943,941 0.027988
PPP1R14A 19 43,433,725 43,439,012 0.027988
TFAP2D 6 50,789,216 50,848,705 0.030387
HMGB1 3 22,398,314 22,572,730 0.031587
NOC4L 12 131,295,223 131,303,216 0.032786
DMRTC2 19 47,040,864 47,047,604 0.034386
TEF 22 40,102,463 40,119,828 0.034386
YIF1B 19 43,487,593 43,498,400 0.035985
FLJ16220 4 132,632,497 132,702,567 0.037584
FAM128A 2 132,075,266 132,083,834 0.037984
MLL5 7 104,248,588 104,348,759 0.038384
PARP8 5 49,998,570 50,173,926 0.040783
GCNT2 6 10,663,935 10,737,586 0.043182
IL17A 6 52,159,144 52,163,395 0.043582
ZNF208 19 20,519,337 20,599,769 0.047580
GALNT9 12 131,347,882 131,516,139 0.048780
The 38 most significant genes (nominal empiric P-Value,0.05) identified by
topology-corrected Prioritizer analysis of 173 non-overlapping CNV regions are
given. Gene start and end positions based on NCBI V35 assembly. Genes related
to glycobiology are in bold. Chr: chromosome.
doi:10.1371/journal.pone.0005324.t002
Table 3. Prioritizer analysis of complex-autism patient CNVs.
Gene Name Chr Gene start Gene end P-Value
GK5 3 143,365,112 143,427,107 0.016793
OVOS2 12 31,155,854 31,245,435 0.019992
TTC4 1 54,893,516 54,920,347 0.023590
METT10D 17 2,268,539 2,361,930 0.043182
ENK11 22 17,307,231 17,308,997 0.047181
The five most significant genes (nominal empiric P-Value,0.05) identified by
topology-corrected Prioritizer analysis of 181 non-overlapping CNVs are given.
Gene start and end positions based on NCBI V35 assembly. Chr: chromosome.
doi:10.1371/journal.pone.0005324.t003
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(B4GALT1, ARSA, and GALNTL5), for which Prioritizer had
determined borderline significance (0.057,nominal p-val-
ue,0.074). These seven genes code for enzymes operating in
different aspects of glycosylation. B3GALT6, B4GALT1, and
GCNT2 participate in N-linked protein glycosylation, while
LARGE, GALNT9, and GALNTL5 are involved in O-linked protein
glycosylation. ARSA functions as one of the main enzymes in lipid
glycosylation. In only one of the healthy controls a heterozygous
loss at chromosome 6p24.3-p24.2, containing the first two non-
coding exons of transcript variant 1of GCNT2 (NM_145649), was
identified. The six remaining glycobiology genes were not affected
by copy-number changes in the control cohort.
CNV validation and segregation analysis
For the seven CNVs that harbor the seven glycobiology-related
genes (Table 4), we performed real-time quantitative PCR (qPCR)
analysis with region-specific primer pairs on the DNA of patients
and their parents, and on two unrelated controls (for primer
sequences see Table S4). The qPCR analysis confirmed the CNV
calls for these seven regions in the patients (four gains, three
hemizygous losses). Genotyping of the parents showed that one
CNV was of paternal origin, three were maternally inherited, and
three had arisen de novo in the patient (Table 4).
Gene expression analysis during murine brain
development (figure 1 about here)
Our finding that enzymes functioning in glycobiology were
overrepresented in CNVs in multiple unrelated non-complex-
autism patients may point towards a role for these enzymes in
brain development. As Prioritizer does not use information
regarding the tissues in which genes are expressed, we performed
an independent expression analysis using mouse transcript-specific
cRNA in situ hybridization for the seven glycobiology-related genes
on murine embryonic and postnatal brain sections, in order to
determine if, when, and where these genes were expressed in the
developing brain (Table S3 and Fig. 1). Transcripts of three of the
candidate genes, B3GALT6, B4GALT1, and GALNTL5, were
ubiquitously expressed throughout the murine embryo, including
the nervous system (Fig. 1, and not shown). More restricted and
specific expression patterns during brain development were
observed for transcripts of LARGE, ARSA, GCNT2 and GALNT9.
Specifically, LARGE transcripts were detected in the embryonic as
well as the adult murine cerebral cortex, and hippocampus. A
slightly more robust expression was observed in the anterior
cerebral cortex in adult brain. Additionally, the Purkinje cells of
the cerebellum showed expression of LARGE in the adult brain.
GALNT9 was expressed in the cortical plate and future
hypothalamus of the embryonic brain. Staining in the anterior
cerebral cortex at E18.5 was more intense, suggestion higher
expression levels in this domain. In the adult brain highest
expression levels of GALNT9 were observed in the cornu ammonis
(CA)1- and CA2-regions of the hippocampus, and layer2/3
pyramidal neurons in the cerebral cortex. Low levels of staining
were observed in the thalamus and granular cell layer of the
cerebellum. ARSA transcripts were detected in the floorplate
neuroepithelium from the midbrain caudally into the spinal cord
at E14.5. At E18.5 staining was observed throughout the cortical
plate, in the mitral cells of the olfactory bulb, and in the thalamus.
In the adult brain, only low intensity staining was present in the
hippocampus, and in the region of the medial vestibular nucleus.
The mitral cells of the olfactory bulb maintained ARSA expression.
The most prominent expression of GCNT2 in the embryonic brain
was in the granular cells of the cerebellum, and the floorplate
neuroepithelium posterior to the midbrain. In the adult mouse
brain staining was present in the CA-regions of the hippocampus,
and in the lateral region of the caudate putamen.
Prioritizer analysis of literature derived autism
susceptibility regions
In order to see whether glycobiology-related genes are
commonly present in regions that confer risk for autism, we
performed an independent Prioritizer analysis of autism suscep-
tibility loci derived from the literature. We recently published an
overview of cytogenetic regions that revealed recurrent aberrations
in autistic individuals [4]. Based on this study we identified seven
cytogenetic regions that each had been identified in more than five
autism cases that showed no chromosomal mosaicism (Table 5).
Additionally, we selected six susceptibility loci that had been
identified in multiple genetic linkage analysis studies (Table 5).
Using Prioritizer, we investigated whether these 13 loci contained
genes with functional relationship to each other, and whether these
genes exert functions comparable to those of the glycobiology-
related genes identified in the Prioritizer analysis of our
microarray-based CNV screen. The top-ten ranked genes from
each locus, from the topology-corrected Prioritizer analysis, are
shown in Table 6. Interestingly, six genes involved in glycobiology
were ranked highly in these loci (median ranked at 8th position).
These genes included B3GALNT2 (1q42.2, ranked 8th out of 138
genes, P = 0.06), B3GALT1 (2q31.1, ranked 10th out of 109 genes,
P= 0.09), GAL3ST2 (2q37, ranked 3rd out of 77 genes, P = 0.06),
B3GNT5 (3q26.32, ranked 5th out of 120 genes, P= 0.06),
GALNTL5 (7q36, ranked 9th out of 105 genes, P= 0.10) and
ARSA (22q13.3, ranked 8th out of 51 genes, P= 0.26), of which the
latter two were also prioritized in the CNVs of the non-complex-
Table 4. CNVs containing genes related to glycobiology in non-complex-autism patients.
Subject Sex Type Chr. CNV Start CNV End Size (kb) Genes Origin
138-003 M Gain 22q12.3 31,759,390 32,408,541 649.15 SYN3, LARGE Paternal
021-003 M Loss 6p24.3–p24.2 10,596,587 10,664,858 68.27 GCNT2 Maternal
104-003 M Gain 9p21.1–p13.3 33,082,835 33,262,424 179.59 B4GALT1, SPINK4, BAG1, CHMP5 Maternal
088-004 F Gain 7q36.1 150,928,784 151,150,935 212.15 PRKAG2, GALNTL5 Maternal
140-003 F Gain 22q13.33 49,353,082 49,368,395 15.31 ARSA De novo
143-003 M Loss 12q24.33 131,285,329 131,370,031 84.70 DDX51, NOC4L, GALNT9 De novo
027-003 M Loss 1p36.33 1,192,554 1,232,438 39.90 SDF4, B3GALT6, FAM132A, UBE2J2 De novo
CNV start and end positions based on NCBI V35 assembly. Genes related to glycobiology in bold. M: male, F: female.
doi:10.1371/journal.pone.0005324.t004
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Figure 1. Expression analysis during mouse brain development of glycobiology-related genes overrepresented in autism-
associated CNVs. a–c: mLarge, d–f: mGalnt9, g–i: mArsa, j,k: mGcnt2, l: mB3galt6. a) At E14.5 mLarge is expressed throughout the nervous system.
The expression in the interior of the medial ganglionic eminence (MGE, (arrow), and in the dorsal root ganglia (DRG’s, arrowheads) is higher then in
surrounding tissues. b) At E18.5 expression is maintained in the nervous system, more intense expression was observed in the cortical plate and the
developing cornu ammonis (CA) regions of the hippocampus (arrow), and in the mitral cells of the olfactory bulb (arrowhead). c) In the adult brain
mLarge expression is high in the cerebral cortex and hippocampus. The anterior cerebral cortex (arrow) and the CA2 region of the hippocampus
(arrowhead) show more intense staining than adjacent cells. In the cerebellum mLARGE is highly expressed in the Purkinje cell layer (asterisk). d) A
low level of mGalnt9 expression was observed in the cortical plate at E14.5, stronger staining was present in the region of the future hypothalamus
(arrow), and in a stripe of cells adjacent to the central canal of the spinal cord (arrowheads). e) At E18.5 neural expression of mGalnt9 has become
restricted to the forebrain, with the exception of the thalamus (asterisk), and some hindbrain nuclei (not shown). The arrowhead and arrow indicate
higher levels of mGalnt9 expression in the anterior cortical plate, and in the hippocampus, respectively. The transition between high and low level
expression in the cortical plate is marked by a dotted line. f) In the adult brain mGalnt9 was expressed in layer II/III pyramidal neurons of the cerebral
cortex, and in the CA1 and CA2 region of the hippocampus. Expression at a lower level was present in the thalamus and in the Purkinje and granular
cell layer of the cerebellum. g) At E14.5 mArsa expression was observed in the floorplate neuroepithelium of the midbrain (arrow), extending caudally
into the spinal cord (arrowheads). A low intensity signal was also present in the thalamus. h) At E18.5 expression of mArsa was maintained
throughout the nervous system, with highest expression in the cortical plate, and thalamus (asterisk). i) In adult brain a low level of mArsa expression
was observed in the CA and DG regions of the hippocampus, and in the granular cell layer of the cerebellum. Additionally, the medial vestibular
nucleus showed expression of mArsa. j) Expression of mGcnt2 in the cerebellar anlage (arrow) at E14.5. k) In the adult brain, mGcnt2 was expressed in
the CA regions of the hippocampus, and in the lateral portion of the caudate putamen. l) mB3galt6 was ubiquitously expressed from E14.5 onwards.
Magnifications: 12.56, except j: 256. Abbreviations: aon: anterior olfactory nucleus, cb: cerebellum, cp: cortical plate, cpu: caudate putamen, dg:
dentate gyrus, hip: hippocampus, liv: liver, lv: lateral ventricle, mb: midbrain, med: medulla oblongata, mf: mesencephalic flexure, nc: neocortex, ob:
olfactory bulb, oe: olfactory epithelium, pf: pontine flexure, thal: thalamus, to: tongue, tri: trigeminal ganglion, sc: spinal cord, smc: primary
somatosensory cortex.
doi:10.1371/journal.pone.0005324.g001
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Table 5. Literature derived autism susceptibility loci.
Locus Chromosomal Location No of Genes Reference
1q42.2 (D1S1656) 217,212,087–237,212,087 138 [30]
2q31.1 (D2S2188) 165,430,238–185,430,238 109 [31]
2q37 233,875,000–243,020,000 77 [4]
3q26.32 (D3S3037) 168,924,373–188,924,373 120 [32]
5p15 0–16,900,000 65 [4]
7q22.1 (D7S477) 90,370,231–110,370,231 193 [31]
7q36.2 (D7S2462) 142,999,403–162,999,403 105 [32]
15q11–14 18,940,000–31,390,000 65 [4]
17q11.2 (D17S1294) 15,406,471–35,406,471 272 [33]
18q21–23 41,800,000–73,160,000 117 [4]
22q11.2 16,970,000–20,830,000 74 [4]
22q13.3 44,555,000–49,550,000 51 [4]
Xp22 0–24,700,000 122 [4]
Total number of genes 1,508
For loci identified through linkage analysis, the microsatellite markers are given between brackets. For each locus (for definition see methods) the chromosomal location
based on the NCBI V35 assembly is provided, including the number of genes contained in the locus.
doi:10.1371/journal.pone.0005324.t005
Table 6. Prioritizer analysis of literature-derived autism susceptibility loci.
Locus Top ten ranked genes from topology-corrected Prioritizer analysis.
1q42.2 (D1S1656) TRIM11 (0.002), NP_115811.1 (0.007), EXOC8 (0.015), ERO1LB (0.015), FMN2 (0.036), HIST3H3 (0.046), DEGS1 (0.047), B3GALNT2 (0.061),
TRIM17 (0.066), SIPA1L2 (0.077)
2q31.1 (D2S2188) LRP2 (0.007), SCN1A (0.012), CYBRD1 (0.015), GAD1 (0.018), MTX2 (0.026), DHRS9 (0.033), NOSTRIN (0.050), ENH1_HUMAN (0.063), SCN2A2
(0.082), B3GALT1 (0.095)
2q37 SEPT2_HUMAN (0.003), NP_612209.1 (0.053), GAL3ST2 (0.060), GPR35 (0.072), SH3BP4 (0.076), RAMP1 (0.121), GBX2 (0.174), MLPH
(0.185), AGXT (0.222), BOK (0.268)
3q26.32 (D3S3037) GAW2_HUMAN (0.008), NP_872343.2 (0.021), NLGN1 (0.042), SIAT1_HUMAN (0.048), B3GNT5 (0.064), NM_003002.1 (0.069), DNAJB11
(0.100), TBL1XR1 (0.136), MYNN (0.142), PSMD2 (0.148)
5p15 SEC6L1 (0.007), NP_954584.1 (0.032), XP_059689.3 (0.046), DAP (0.143), SLC9A3 (0.165), SRD5A1 (0.187), MTRR (0.219), IRX1 (0.281),
SLC12A7 (0.284), SLC6A3 (0.292)
7q22.1 (D7S477) CYP3A5 (0.003), CYP3A7 (0.003), CYP3A43 (0.003), CYP3A4 (0.007), GJE1 (0.008), FZD1 (0.019), MCM7 (0.035), BCAP29 (0.056), KRIT1 (0.058),
MLL5 (0.059)
7q36.2 (D7S2462) EFC2_HUMAN (0.007), PDIA4 (0.016), NP_065178.1 (0.030), ABCB8 (0.046), SHH (0.059), RNF32 (0.065), DPP6 (0.092), GIMAP6 (0.096),
GALNTL5 (0.102), NOS3 (0.103)
15q11–14 MKRN3 (0.009), TUBGCP5 (0.011), O60374_HUMAN (0.031), UBE3A (0.051), NIPA2 (0.078), NP_001019852.1 (0.128), KLF13 (0.144),
NP_061831.1 (0.161), NP_055782.2 (0.260), GREM1 (0.370)
17q11.2 (D17S1294) ALDH3A1 (0.011), PRR6 (0.015), ALDH3A2 (0.020), Q6NXQ4_HUMAN (0.026), PIGW (0.030), ACCN1 (0.039), ZPBP2_HUMAN (0.040), PIGS
(0.049), DUSP14 (0.050), PM1_HUMAN (0.057)
18q21–23 FECH (0.013), RAB27B (0.023), POLI (0.030), PIGN (0.039), KIAA0427 (0.044), MBP (0.106), ST8SIA5 (0.120), ZNF236 (0.123), CNDP1 (0.140),
PHLPP_HUMAN (0.157)
22q11.2 SLC25A1 (0.004), SDF2L1 (0.019), ENK11_HUMAN (0.034), DGCR2 (0.073), GSCL (0.075), RTN4R (0.092), COMT (0.108), PPM1F (0.152), CLDN5
(0.177), SEPT5 (0.233)
22q13.3 TUBGCP6 (0.006), MLC1 (0.046), ALG12 (0.070), MAPK11 (0.113), ADM2 (0.125), CERK (0.128), MAPK8IP2 (0.213), ARSA (0.260), PLXNB2
(0.286), TBC1D22A (0.301)
Xp22 MID1 (0.005), PCYT1B (0.015), NLGN4X (0.015), HCCS (0.020), ASMT (0.034), Q7Z4W4_HUMAN (0.040), CNKSR2 (0.040), GLRA2 (0.068),
PLCXD1 (0.095), PTCHD1 (0.120)
The ten most significant genes identified from topology-corrected Prioritizer analysis of the 13 non-overlapping literature-derived autism susceptibility loci are given per
locus (sorted on P-Value). Genes related to glycobiology are in bold. P-values for individual genes are given between brackets.
doi:10.1371/journal.pone.0005324.t006
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autism group. Although individual determined empiric P-Values
for these glycobiology genes were not significant, these results are
suggestive that analysis of loci previously implicated in autism also
ranks genes functioning in glycobiology high.
Discussion
Recently, a number of studies have highlighted the causal role
genomic CNVs may play in the occurrence of autism and ASD
[4,5,8,9]. Whereas these studies showed that a large percentage of
autism patients carry potentially harmful genomic gains or losses,
remarkably few of these aberrations were found to be recurrent.
The size of the CNVs and the high degree of genetic heterogeneity
among patient cohorts are factors that have hampered identifica-
tion of susceptibility genes within the autism-associated CNVs.
Consequently, candidate gene selection has remained a highly
biased process. An additional problem has been the high degree of
variability in the clinical features and co-morbidities of individual
autism patients used for these studies, which may obscure the
identification of risk genes acting in a subgroup of patients.
Taking these matters into account and trying to minimize
confounding effects, we set out to perform a high resolution,
genome-wide CNV screen in a genetically homogeneous Dutch
autism cohort, followed by subsequent candidate gene selection of
the genes in these CNVs using a novel bioinformatics tool,
Prioritizer. Furthermore, the genes in 13 literature-derived autism
susceptibility loci, including linkage regions and cytogenetically
relevant regions, were analyzed as cross reference for the gene
analysis of our initial CNV data.
First, to obtain a more uniform patient cohort and limiting the
variability in clinical features, focusing strictly on autism, we
applied a slightly modified version of a clinical checklist to clinical
data obtained from our patients (see methods). This resulted in the
formation of two autism patient groups; non-complex-autism and
complex-autism. The phenotype of the two groups differed in the
number of abnormalities in family history, growth disorders, and
dysmorphic features or congenital anomalies. The non-complex-
autism phenotype group was characterized by little or none of the
aforementioned abnormalities, the complex-autism phenotype
group was typified by the presence of multiple abnormalities.
Similar to the original assumption by de Vries et al.[16], we
hypothesized that these phenotypical differences may reflect a
difference in the genomic defects underlying the disorder.
However, no significant difference in the number or size of CNVs
was observed between these patient groups, suggesting that the
genes within these regions are responsible for the difference in
phenotypes, not the total number of genes that are affected by
genomic gain or loss.
Second, we identified a number of plausible novel autism
candidate genes from our CNV regions using Prioritizer [11]. The
Prioritizer analysis of CNVs in the non-complex-autism group has
yieldedmeaningful data, since several of the genes highly ranked have
previously been associated with cognitive or neuropsychiatric
disorders. Retinoic acid induced 1 (RAI1), located in an unstable region
on chromosome 17p11.2, is involved in Smith-Magenis syndrome
(MIM182290) [17,18], a disorder with cognitive impairment and
behavioral abnormalities. Bromodomain-containing protein 1 (BRD1), at
chromosome 22q13, has recently been associated with schizophrenia
and bipolar affective disorder [19]. The LARGE gene, at 22q12.3, has
recently been implicated in Walker-Warburg syndrome [20], a rare
autosomal recessive disorder with mental retardation and muscular
dystrophy, and disruption of the LARGE gene was observed in a
patient with schizophrenia [21]. Moreover, these neuropsychiatric
disorders display several clinical features that overlap with autism.
Many other genes with known or putative functions in neuronal
development, axon growth, and synaptic function were ranked
highly, including neurotrimin (NTM), piccolo (PCLO), D4 zinc and double
PHD fingers family 1 (DPF1, also called NeuD4) and S100 calcium binding
protein A5 (S100A5). These genes show highly restricted brain
expression patterns (The Allen brain atlas, www.brain-map.
org)[22], specifically in brain regions where morphological alterations
in post-mortem brains of autism patients have been identified (e.g.
cerebral cortex, cerebellum, and hippocampus). In addition, these
observations strengthen findings from structural and functional
Magnetic Resonance Imaging studies [23].
Third, gene-network analysis of susceptibility genes in the non-
complex-autism group and in 13 literature-derived autism-
susceptibility loci revealed an overrepresentation of genes related
to glycobiology, and suggests that dosage alterations in these genes
could contribute to the autism phenotype. Congenital disorders of
glycosylation (CDGs) are genetic diseases caused by defects in the
synthesis, metabolism or functions of glycans, impacting on N- or
O-linked protein glycosylation as well as lipid glycosylation
[24,25]. Whereas CDGs almost invariably show autosomal
recessive inheritance and very severe disease phenotypes, the
effects of gene dosage changes, as observed in autism patients, may
reflect the expression of less severe dysfunction of the pathways in
which these genes operate. Pedigree analysis of the patients
carrying gains and losses of the glycobiology-related genes is in
good agreement with a recently reported model for the genetics of
autism, postulating that autism is mainly caused by either de novo
mutations with high penetrance in males, or by mutations that are
inherited from an unaffected mother [10].Three of the seven
CNVs occurred de novo in the patients, and the other four CNVs
were inherited from apparently unaffected parents, mostly of
maternal origin (3 out of 4). The inheritance pattern shows that the
effects of the observed gene dosage changes may not be fully
penetrant, and interaction with other factors may be required to
produce an autism phenotype.
The seven glycobiology-related genes identified in CNVs in our
autism cohort are expressed in developing murine brain regions
known to be altered in the human autistic brain. The essential role of
protein glycosylation for normal brain development has been
demonstrated by the severe brain phenotypes in Walker-Warburg
syndrome and Muscle-Eye-Brain disease. These syndromes are
caused by protein O-mannosyltransferase deficiencies resulting in
truncation of the O-proteoglycan core. Also brain abnormalities
resulting from defects in protein N-glycosylation have been found,
while ARSA (arylsulfatase A)-deficiency leads to motor and mental
symptoms (see below). In the present study we encountered genomic
losses and gains in genes encoding enzymes involved in all of these
glycosylation pathways. O-glycosylation was represented by LARGE
(dup), GALNT5 (dup) and GALNT9 (del). Interestingly, a schizophre-
nia patient with a disruption in the LARGE gene [26] and the autism
patient in the present study both carry a intragenic gain that may
result in an internal disruption of the LARGE gene. N-glycosylation
was represented by B3GALT6 (del), B4GALT1 (dup) and GCNT2 (del).
Deficiencies of beta1,3- and beta1,4-galactosyltransferases, particu-
larly B3GALTL and B4GALT1, lead to neuronal phenotypes:
B3GALTL deficiency, either by bi-allelic truncating mutations or by
combination of genomic loss and point mutation, causes Peters Plus
syndrome (MIM261540), an autosomal recessive syndrome with
multiple symptoms including psychomotor retardation [27]. Psycho-
motor retardation was also observed in a patient with B4GALT1
deficiency caused by a homozygous truncating mutation [28],
indicating that galactosyltransferases play a role in development of
the brain. GCNT2 gives rise to the developmental I antigen of which
some mutations cause cataract (MIM110800). No brain phenotypes
Autism Gene-Network Analysis
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are known, but our expression analysis shows that CGNT2 displays a
distinct spatiotemporal expression pattern suggestive for a function
during brain development. The ARSA gene encodes the lysosomal
enzyme arylsulfatase A, involved in cerebroside metabolism.
Homozygous or compound heterozygous ARSA mutations cause
metachromatic leukodystrophy (MLD, MIM250100) that displays
early, late and adult forms, all with neurological and neuropsychiatric
symptoms. In this study we report a gain of ARSA that could result in
a gain-of-function of ARSA.
The fact that genomic gains as well as losses in these pathways
appear to contribute to autism suggests that the ratios of the
enzymes encoded by these genes is tightly regulated in the brain,
and that changes in stoichiometry may lead to aberrant sugar
chains on their protein substrates. Therefore, it will be paramount
to identify the protein targets of these glycobiology-related genes in
the brain, and to study their function. This will further increase
our insight in the mechanisms by which they influence brain
development, and how they can lead to neuropsychiatric disorders
when functionally impaired. Ultimately, new possibilities for the
development of pharmacological intervention strategies in the
treatment of autism may emerge.
Materials and Methods
Ethics Statement
All subjects included in the study gave written informed consent,
and the local Medical Ethics Review Boards approved all
procedures.
Patient and control cohort selection for genome-wide
CNV analysis
At the department of Child and Adolescent Psychiatry of the
UMC Utrecht an extensive repository of peripheral blood,
genomic DNA, and phenotypic data on autism patients has been
collected over the past 2 decades for research purposes. For autism
patients, multidisciplinary evaluation included the Autism Diag-
nostic Interview – Revised (ADI-R)+/2the Autism Diagnostic
Observation Schedule generic (ADOS-G). Clinical diagnosis was
established by an experienced clinician who studied medical
records, developmental history and available diagnostic informa-
tion. All autism patients had above cut-off score for autism on the
ADI-R/ADOS-G and were diagnosed according DSM-IV(TR)-
criteria. Exclusion followed if ADI-R cut off criteria were not met,
or if medical illness was present. A priory, the patients carrying
known genetic defects (e.g. FMR1 or TSC1/2 mutations, major
cytogenetic abnormalities on karyogram) were excluded from this
study. From the remaining cases, a total of 105 subjects were
selected for this study. The patient cohort almost entirely consisted
of patients with autism and Asperger syndrome. In collaboration
with several clinical geneticists in our hospital we applied a
modified checklist, that was originally designed to assess the
probability of a phenotype being caused by chromosomal
aberrations in patients with mental retardation [16], to our autism
patients medical statuses and medical reports. In this way we
aimed to investigate whether a difference in genetic susceptibility
exists between patients with only autism and patients with autism
and additional abnormalities, and if the use of this prescreening
tool could be extended to psychiatric disorders. The criteria we
used to subdivide the phenotype according to clinical features are;
a positive family history of autism and/or mental retardation,
prenatal onset growth retardation (birth weight less than p3,
according to gestational age), postnatal growth abnormalities
(height or head circumference below 22 SD or above +2 SD,
according to age), facial dysmorphic features and non-facial
dysmorphic features or congenital anomalies. Subdividing the 105
subjects according to these clinical features resulted in the
formation of two patient groups; the first group of autism patients
(non-complex-autism group, n = 53) contained subjects with no or
little of the aforementioned abnormalities. The second group of
autism patients (complex-autism group, n= 52) consisted of
subjects with more of the aforementioned abnormalities Addition-
ally, 267 ethnically matched, unrelated, healthy volunteers
(recruited by the Department of Neurology in the University
Medical Center Utrecht) were included in this study. All controls
were of self-declared Dutch descent with all four grandparents
originating from The Netherlands.
Autism susceptibility loci from genome-wide CNV
analysis
Genomic DNA was isolated with a salting out procedure and
genotyped using HumanHap300 Genotyping Beadchips (Illumina)
as described [29]. All procedures were performed according to the
manufacturer’s protocol; 750 ng of genomic DNA was amplified,
fragmented and hybridized to the array. Products were then
fluorescently labeled and scanned using the Illumina Beadstation
scanner. Raw data was uploaded in Beadstudio V2.3.41
genotyping software (Illumina) for further analysis. At the time
of analysis of this study no automated CNV detection method was
available for HumanHap300 Genotyping Beadchip data; therefore
we formulated a script to detect three chromosomal aberration
types from the Beadstudio analysis results: heterozygous deletions,
homozygous deletions, and duplications (for detailed method see
[15]). In short, heterozygous deletions were called when a series of
SNPs showed absence of heterozygous genotypes (loss of
heterozygosity, due to A/- or B/- genotypes) with negative
deflections in the log2 R ratio. Homozygous deletions were defined
as series of SNPs with strongly negative intensity signals (log2 R
ratio,23.0). Duplications were defined as series of SNPs with
increased log2 R ratios, in the presence of B allele frequency values
of ,0?33 (AA/B genotypes) or ,0?66 (A/BB genotypes).
Definition of literature derived autism susceptibility loci
In this study, the literature derived loci for autism were based on
data from four linkage studies [30–33] with multipoint logarithm of
the odds score (MLS) above 3.0 [34], and the collected data from a
large volume of cytogenetic studies [4]. Boundaries of the linkage
regions were defined by a 20 MB basepair block centered around the
most significantly linked marked in each locus. In these linkage based
studies, cases with known cytogenetic aberrations have been
excluded. Definition of the Cytogenetic Regions Of Interest (CROIs)
was based on criteria which have been described before [4]: In short,
regions on the human genome where multiple overlapping
cytogenetic abnormalities co-occurred with an autism phenotype
were identified through an extensive literature search. Cases involving
chromosomal mosaicism or well described gene mutation as the most
likely genetic cause for autism were excluded (e.g. patients with
fragile-X syndrome caused by FMR1 mutations). Accurate base pair
positions of the linkage regions and CROIs were derived by mapping
all available probe and/or banding information from the case reports
to the NCBI V35 assembly. In the present study, only CROIs that
contained more than 5 overlapping cases were selected for the
analysis. In total 13 loci were defined of which six were based on
linkage data and seven were based on cytogenetic data.
Prioritization of positional autism candidate genes
To assess whether certain biological pathways were overrepre-
sented with genes, mapping within the CNV regions that had been
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identified in the autistic individuals we used Prioritizer [11].
Prioritizer uses a reconstructed functional human gene network to
prioritize genes residing in multiple loci, by assuming that real
causal genes are more closely related within the human gene
network than other genes. In order to establish accurate empiric P-
values we used a permutation based, topology-corrected method.
This permutation strategy assumes that in each permutation, the
loci can be randomly shuffled across the genome. However, as we
had only used the SNPs that are present on the Illumina
HumanHap300 platform to identify CNVs, random shuffling of
these loci will introduce a bias. To overcome this, we adapted
Prioritizer’s permutation procedure: We first determined what
relationships exist between the genes that map within the CNVs
identified either in non-complex-autism patients or in complex-
autism patients. Subsequently, in each permutation we sampled an
equal amount of CNVs from a set of CNVs that comprised both
the 267 controls and either the non-complex or or complex-autism
groups, respectively. While the inclusion of these patients in the
permutation results in some loss of statistical power to detect
significantly overrepresented pathways, this strategy ensures that
all permuted loci reflect CNVs that have at least been identified
once, resulting in a null-distribution that is not biased (data not
shown).
Validation and inheritance analysis of CNVs in autism
pedigrees
Real-time quantitative PCR was performed on 40 ng of
genomic DNA from the patients, both parents and 2 non-related
controls (one male and one female) for the genes functioning in
protein and lipid glycosylation. Region specific primer pairs for
each CNV were designed using primer3 [35](Table S4). Reactions
were carried out in duplo in a LightCycler 2.0 Real-Time PCR
System (Roche Applied Science), using LightcyclerH Faststart
DNA MasterPLUS SYBR Green I (Roche Applied science)
according to the manufacturers protocols. Calculation of relative
DNA quantities was performed using qBASE analyzer, version
1.3.5 [36].
RNA in situ hybridization during mouse brain
development
A detailed description of this method was reported previously
[37]. In short, transcript specific sequences for the genes involved
in protein glycosylation were amplified from embryonic day (E)
14.5 mouse brain total RNA using transcript specific primer
sequences (Table S5) and the OneStep RT-PCR kit (Qiagen). The
RT-PCR products were subsequently cloned into the pGEM-T-
easy vector (Invitrogen), and DIG-labeled cRNA probes were
made using T7 or Sp6 dependent RNA polymerase (Roche
Applied Science). Sense and antisense probes were hybridized to
16 mm sagital cryosections of various mouse embryonic stages
(E14.5, E16.5 and E18.5) and adult mouse brain, and expression
was visualized using NBT-BCIP (Roche Applied Science). Images
were recorded on a Zeiss Axioskop2 Plus microscope with a Sony
Power HAD DXC-950P 3CCD color video camera. Expression
was considered genuine only when sections hybridized with the
corresponding sense probe showed no significant staining.
Supporting Information
Table S1 Prioritizer input for the non-complex-autism patient
group. The 210 CNVs identified in 53 patients with non-complex-
autism were combined into 173 non-overlapping unique copy-
number variant regions (CNVR) for analysis. Nucleotide positions
for the CNVR start and end were based on the NCBI V35
assembly. Chr: chromosome.
Found at: doi:10.1371/journal.pone.0005324.s001 (0.23 MB
DOC)
Table S2 Prioritizer input for the complex-autism patient group.
The 242 CNVs identified in 52 patients with a complex-autism
phenotype were combined into 181 non-overlapping unique
CNVR for analysis. Nucleotide positions for the CNVR start
and end were based on the NCBI V35 assembly. Chr:
chromosome.
Found at: doi:10.1371/journal.pone.0005324.s002 (0.25 MB
DOC)
Table S3 Summary of expression analysis by RNA in situ
hybridization during murine brain development of glycobiology-
related genes associated with autism. Genes from de novo
occurring copy-number changes are in bold. CNS: central nervous
system, PNS: peripheral nervous system, MGE: medial ganglionic
eminence, DG: dentate gyrus.
Found at: doi:10.1371/journal.pone.0005324.s003 (0.03 MB
DOC)
Table S4 Primer sequences for real-time quantitative PCR
analysis on human genomic DNA. Primers were designed using
Primer3 (see methods).
Found at: doi:10.1371/journal.pone.0005324.s004 (0.03 MB
DOC)
Table S5 Primers sequences for generation of cRNA in situ
hybridization probes from mouse RNA. Primers were designed
using Primer3 (see methods).
Found at: doi:10.1371/journal.pone.0005324.s005 (0.03 MB
DOC)
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